20/20 BIOLABS, INC. Retained Earnings
20/20 BIOLABS, INC. (AIDX) had Retained Earnings of -$36.93 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-14
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$36.93M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$35.42M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$33.25M.
- 2024-12-31: Retained Earnings (Accumulated Deficit) -$29.51M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$36.93M 10-Q · filed 2026-08-14 |
| 2026-03-31 | -$35.42M 10-Q · filed 2026-05-20 |
| 2025-12-31 | -$33.25M 10-Q · filed 2026-08-14 |
| 2024-12-31 | -$29.51M POS AM · filed 2026-04-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGENOMICS INC (NEO) | United States | $2.514B | -35.96 |